AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05021887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
Description: 2 inhalations of Test and Reference product in each study period
Study NCT05021887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT DISKUS
Description: 2 inhalations of Test and Reference product in each study period
Study NCT04934852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: When elderly patients had hypotension (invasive blood pressure drops >20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
Study NCT04934852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: When elderly patients had hypotension (invasive blood pressure drops >20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
Study NCT04934852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: When elderly patients had hypotension (invasive blood pressure drops >20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
Study NCT04380545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04380545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04380545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alpha 2b-like Protein
Description: Given SC
Study NCT05298592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986406
Description: Specified dose on specified days
Study NCT04964479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: 1200mg injection once every 3 week
Study NCT04964479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: 12mg capsule once daily
Study NCT04964479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: 200mg injection once every 3 week
Study NCT04964479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily
Study NCT05515042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
Description: As included in arm/group descriptions
Study NCT05298592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT06428396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg administered as an IM injection.
Study NCT06428396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg administered as an IM injection.
Study NCT06428396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Administered at 10mg via oral tablets QD.
Study NCT06428396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Administered at 25 mg via oral tablets QD.
Study NCT05743309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video call sessions
Description: Investigators made video call sessions with the participants.
Study NCT05320367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis, placebo
Description: Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
Study NCT04930393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block - either PECS II or axillary ring
Description: In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
Study NCT01063686 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: insemination cervical cap
Description: Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
Study NCT06631495 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: not available-observation study
Study NCT06628518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily oriented Mindfulness informed Legal Education (FAMiLE)
Description: The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a low-intensity intervention involving four sessions. The session will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The Family oriented component will include stress management, including coping techniques and problem-solving, positive communication, behaviour modification and parenting, and a session on consolidation including sustaining gains. The intervention will also incorporate positive parenting and interactions with children.
Study NCT05483374 — intervention group
Intervention type: OTHER
Intervention: observation
Description: Not applicable, it is an observational registry
Study NCT06376214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation (ASCT)
Description: The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~.
Study NCT04960345 — intervention group
Intervention type: DEVICE
Intervention: Brainlab Knee 3
Description: Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
Study NCT05681195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive 900 mg/m\^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.
Study NCT05681195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression.
Study NCT05681195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols
Study NCT05681195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy (WBRT)
Description: WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
Study NCT05298592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT05298592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT05298592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT05434130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Dose Exercise
Description: The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
Study NCT04084574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet counseling
Description: Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
Study NCT04084574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH diet counseling
Description: Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
Study NCT06553573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parasternal Block and Recto-İntercostal Fascial Plane Block
Description: Parasternal Block and Recto-Intercostal Fascial Plane Block:Superficial PSB is performed bilaterally with the patient in the supine position using a high-frequency linear USG probe. The probe is inserted longitudinally 2cm lateral to the sternal border to visualize the T2T4 intercostal space and identify the pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is administered between the pectoralis major and intercostal muscle. Additionally, a Recto-Intercostal Fascial Plane Block is performed bilaterally with a high-frequency linear USG probe. The probe is inserted 2-3cm lateral to the xiphoid to visualize the rectus abdominis muscle and the 6th-7th cartilages. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique, and 1-2ml of saline is injected. After spreading to the target plane is observed, 20ml of 0.25% bupivacaine is administered.
Study NCT06553573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parasternal Block and Erector Spinae Plane Block
Description: Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2cm lateral to the sternal border to identify the T2T4 intercostal space, pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is applied between the pectoralis major and intercostal muscle. Additionally, an erector spinae plane block is performed with a high-frequency USG probe. Erector spinae plane block is performed under general anesthesia, in the lateral position, under USG guidance, after sterilization, by inserting a needle between the deep surface of the erector spinae muscle and the transverse process with an in-plane approach in the craniocaudal direction. If no air or blood is seen in the aspiration, a 2mL serum test dose is applied to this area and a total of 20mL of 0.25% bupivacaine is injected bilaterally to perform an erector spinae plane block.
Study NCT04536077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: The drug will be supplied free of charge by Celldex
Study NCT04536077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: The drug will be supplied free of charge by Celldex
Study NCT04536077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
Study NCT05249972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Description: Topical cutaneous spray
Study NCT04878627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: patients receive cannabidiol at various doses for 3 weeks
Study NCT04878627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients receive placebo for 3 weeks
Study NCT05702710 — intervention group
Intervention type: OTHER
Intervention: Surgery (PIRS)
Description: Laparoscopic procedure for repair of inguinal hernia as described in:~1) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889.
Study NCT05141890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Plantarum
Description: Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
Study NCT05249972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Description: Topical cutaneous spray
Study NCT06477302 — intervention group
Intervention type: BEHAVIORAL
Intervention: Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer (STA-RR-LC)
Description: Patients will be given a measurement instrument to determine the level of therapeutic adherence.
Study NCT04990219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 - capsule
Study NCT04990219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - capsule
Study NCT05010304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Two-dose amoxicillin challenge
Study NCT05249972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Description: Topical cutaneous spray
Study NCT05249972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Description: Topical foam
Study NCT06113406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Training
Description: Active Comparator
Study NCT06113406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: Experimental
Study NCT05839938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D (2000IU/day) for 6 months
Study NCT05839938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05249972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Description: Topical foam
Study NCT05249972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
Description: Topical foam
Study NCT05249972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cutaneous spray
Study NCT04698590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront Guided Scleral Lenses
Description: Custom wavefront guided, higher order aberration correcting scleral lenses
Study NCT04698590 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Scleral Lenses
Description: Traditional scleral lenses
Study NCT05249972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo cutaneous spray
Study NCT05249972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cutaneous spray
Study NCT04729608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Batiraxcept is an experimental drug
Study NCT04729608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is the standard of care, background therapy
Study NCT04729608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is the standard of care, background therapy
Study NCT04729608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05005819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] APN-1607
Description: Subjects will undergo PET imaging using \[18F\]APN-1607.
Study NCT05279092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Liposomal Bupivacaine
Description: Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
Study NCT05279092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
Description: Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
Study NCT04678830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos
Study NCT04678830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab (700mg)
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study NCT04649489 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: atezolizumab 1200mg and bevacizumab 15mg/kg
Study NCT04649489 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
Study NCT05999279 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
Study NCT06333951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO
Study NCT06333951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study NCT06333951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study NCT06333951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study NCT06020482 — intervention group
Intervention type: OTHER
Intervention: Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity
Description: The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
Study NCT05488886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Aronia Berry Powder Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).
Study NCT05488886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia Berry Extract Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).
Study NCT05488886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phospholipid-Polyphenol Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).
Study NCT05488886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Polyphenol Control Applesauce
Description: The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.
Study NCT05890508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
Study NCT05890508 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-acupuncture
Description: Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation.
Study NCT04682028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: professional care
Description: The trained nurses provide professional care for the patients.